Compare IDXX & MDLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IDXX | MDLN |
|---|---|---|
| Founded | 1983 | 1966 |
| Country | United States | United States |
| Employees | N/A | 45000 |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 45.4B | 37.4B |
| IPO Year | 1996 | N/A |
| Metric | IDXX | MDLN |
|---|---|---|
| Price | $556.20 | $39.70 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 23 |
| Target Price | ★ $721.67 | $50.48 |
| AVG Volume (30 Days) | 592.1K | ★ 6.7M |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 22.59 | N/A |
| EPS | ★ 3.47 | N/A |
| Revenue | ★ $4,303,702,000.00 | N/A |
| Revenue This Year | $10.88 | $10.88 |
| Revenue Next Year | $8.59 | $7.69 |
| P/E Ratio | ★ $156.86 | $658.75 |
| Revenue Growth | ★ 10.42 | N/A |
| 52 Week Low | $518.55 | $32.82 |
| 52 Week High | $769.98 | $50.88 |
| Indicator | IDXX | MDLN |
|---|---|---|
| Relative Strength Index (RSI) | 50.84 | 53.96 |
| Support Level | $549.60 | $38.08 |
| Resistance Level | $583.93 | $43.87 |
| Average True Range (ATR) | 16.50 | 1.66 |
| MACD | -1.00 | -0.22 |
| Stochastic Oscillator | 47.99 | 56.43 |
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx derives roughly 35% of its revenue from outside the United States.
Medline is the largest medical-surgical products and supply chain solutions provider in the US. The company generates over 90% of its revenue domestically and serves some of the largest US health systems. Medline offers approximately 190,000 Medline-branded products across more than 250 product families—including front line care, surgical solutions, and laboratory and diagnostics—as well as roughly 150,000 third-party products sourced from over 1,250 vendors. The company maintains prime vendor relationships with many customers, acting as the primary consolidated logistics partner for their medical-surgical needs. Medline has significant scale, supported by more than 30 manufacturing facilities and a fleet of over 2,000 owned delivery trucks. Medline went public in December 2025.